Towards the Validation of Novel Tau PET tracer [F-18]-AV-1451 (T807) on Postmortem Brain Tissue

Teresa Gómez-Isla, MD, PhD
Massachusetts General Hospital
Harvard Medical School
Massachusetts ADRC
• Development of novel tau targeting PET tracers opens an exciting opportunity of using them as potential surrogate markers to measure brain tau pathology by *in vivo* imaging.

• Anticipated challenges:

  ✓ Tau deposits are *intracellular*.

  ✓ Need for tracers with **high binding selectivity** for tau lesions over β-amyloid (Aβ) plaques and other amyloid-like proteins able to form deposits with a β-pleated sheet conformation.
• Differences of brain tau deposits in each tauopathy potentially associated with altered ability to be identified by tau PET tracers:

✓ **Regional distribution** of tau deposits in the brain

✓ **Morphology:**
  - Tangles, neuropil threads and dystrophic neurites - AD
  - Pick bodies - PiD
  - Coiled bodies, globose tangles and tufted astrocytes - PSP
  - Astrocytic plaques, coiled bodies and neuropil threads – CBD

✓ **Isoform composition**
  - Mixture of 3R+4R - AD
  - 3R - PiD
  - 4R - PSP and CBD

✓ **Ultrastructural characteristics of tau filaments**
  - Paired helical filaments - AD
  - Straight filaments - PiD, PSP and CBD
### Chemical structures of novel tau compounds

<table>
<thead>
<tr>
<th>Ligand</th>
<th>Structure</th>
<th>Affinity for Tau [nM]</th>
<th>Specificity for Tau relative to Aβ</th>
<th>Mouse brain uptake at 2 min [%ID/g]</th>
<th>Mouse brain washout (2min/30 min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C-PBB3</td>
<td><img src="image1" alt="Structure" /></td>
<td>$K_d = 2.5$</td>
<td>40- to 50-fold</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>F-THK523</td>
<td><img src="image2" alt="Structure" /></td>
<td>$K_d = 1.90^{11}$</td>
<td>15-fold</td>
<td>2.72</td>
<td>1.9</td>
</tr>
<tr>
<td>F-THK5105</td>
<td><img src="image3" alt="Structure" /></td>
<td>$K_d = 1.46^{12}$</td>
<td>25-fold</td>
<td>9.2</td>
<td>2.6</td>
</tr>
<tr>
<td>F-THK5117</td>
<td><img src="image4" alt="Structure" /></td>
<td>$(K_d = 10.5)^{13}$</td>
<td>(NA)</td>
<td>6.06</td>
<td>10.3</td>
</tr>
<tr>
<td>F-T807</td>
<td><img src="image5" alt="Structure" /></td>
<td>$K_d = 14.6$</td>
<td>&gt;25-fold</td>
<td>4.16</td>
<td>6.7</td>
</tr>
<tr>
<td>F-T808</td>
<td><img src="image6" alt="Structure" /></td>
<td>$K_d = 22^{14}$</td>
<td>27-fold</td>
<td>6.7</td>
<td>2.9</td>
</tr>
</tbody>
</table>

* $K_d$ determined by ligand-binding to Tau-positive human brain sections
* $K_d$ determined by ligand-binding to Tau-fibrils
* $K_d$ determined by competitive inhibition of $^{18}$F-THK5105 to Tau-fibrils
* 2.5 min; § washout 2.5 min/20 min
* NA= Not available; N.B. The affinity values for various ligands are generated from different types of experiments and may not always be directly comparable.
• Screening of hundreds of compounds, originally designed to bind Aβ deposits, carbazoles yielded good candidates for selective tau binding – T726 (fluorescent).

• *In vivo* and *in vitro* properties of T726 were optimized further. A close analogue, AV-1451 (T807), designed to specifically bind PHF-tau, emerged as the lead candidate.

• AV-1451 (T807) and T726 structures are not identical.
• >25 fold selectivity for PHF-tau over Aβ
• Good overlap with PHF staining but not with Aβ
• Little white matter binding
• Non-detectable/minimal off-target binding

[Introduction]

Correlation of [F-18]-AV-1451 ARG and PHF1/Aβ IHC

[Diagram showing correlation graphs]

[18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer’s disease

Chun-Fang Xia, Janna Arteaga, Gang Chen, Umesh Gangadharath, Luis F. Gomez, Dhanalakshmi Kasi, Chung Lam, Qianwa Liang, Changhui Liu, Vani P. Mocharla, Fanrong Mu, Anjana Sinha, Helen Su, A. Katrin Szardenings, Joseph C. Walsh, Eric Wang, Chul Yu, Wei Zhang, Tieming Zhao, Hartmuth C. Kolb

Molecular Imaging Biomarker Research, Siemens Medical Solution USA, Inc, Culver City, CA, USA
Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807

Introduction

HCS MCI mild AD severe AD

<table>
<thead>
<tr>
<th>Cblm</th>
<th>WM</th>
<th>MTemp</th>
<th>LTemp</th>
<th>Par</th>
<th>Fro</th>
<th>Ocp</th>
</tr>
</thead>
</table>

| Hpc |

HCS (67 years old, MMSE 30) MCI (69 years old, MMSE 26) HC (56 years old, MMSE 29) AD (88 years old, MMSE 21) HC (58 years old, MMSE 29) AD (72 years old, MMSE 7)
We aimed at examining region and substrate specific autoradiographic binding patterns of [F-18]-AV-1451 in brain postmortem tissue samples representing a diverse spectrum of neurodegenerative diseases in order to:

- **Validate the site/s of [F-18]-AV-1451 binding.**
- **Determine whether there is any off-target binding.**

*Early time in tau imaging, yet this compound is quickly making its way into use in clinical research including secondary prevention trials in AD like the A4 trial.*
Cases (n=24)

- Alzheimer’s disease (n=3)
- Frontotemporal dementia-tau:
  - Pick disease (n=3)
  - Progressive supranuclear palsy (n=3)
  - Corticobasal degeneration (n=2)
- Dementia with Lewy bodies (n=3)
- Multiple System Atrophy (n=1)
- Frontotemporal dementia-TDP-43 (n=1)
- CAA, Iowa D23N APP mutation (n=1)
- Healthy controls (n=2)
- Metastatic melanoma (n=1)
- Superficial siderosis (n=1)
- Hemorrhages (n=3)

Brain regions

- Frontal cortex
- Parietal cortex
- Temporal cortex
- Occipital cortex
- Hippocampus/entorhinal cortex
- Insula
- Cingulate
- Basal ganglia
- Subcortical white matter
- Midbrain
- Pons
- Cerebellar cortex
- Dentate nucleus
- Leptomeninges
(1) **[F-18]-AV-1451 phosphor screen autoradiography**

- Frozen sections thawed + fixed with Methanol x 20min
- **[F-18]-AV-1451 (20μCi/ml)** 60min incubation + washes with PBS and EtOH + air dried
- Adjacent sections with identical conditions + unlabeled AV-1451 (1μM) (“blocking”) to saturate available tau binding sites
- Phosphor screen (MultiSensitive Phosphor Screen, PerkinElmer Life and Analytic Sciences) overnight
- Imaging system (Cyclone Plus Storage Phosphor Scanner, Perkin Elmer Life and Analytic Sciences)
A **photographic nuclear emulsion** consists of a thin layer of radiation-sensitive **silver crystals** suspended in a gelatin matrix which is supported by a glass plate.

When silver grains are struck by radiation (photons or electrons), they are altered chemically to form a latent image of the silver crystals.
(2) [F-18]-AV-1451 nuclear emulsion autoradiography

- Frozen sections thawed + fixed with Methanol x 20 mins

- [F-18]-AV-1451 (20μCi/ml) 60min incubation + washes with PBS and EtOH + air dried

- Dip the slides x 8 into Ilford photographic emulsion (1:5 in H₂O) in a dark room, left overnight laying flat in a dark box

- The following day: developed with Ilford Phenisol X-ray developer, fixed with Ilford fixative

- Followed by:
  - IHC
  - H&E staining
(3) [H3]-AV-1451 binding assay

• Fresh-frozen human brain samples are homogenized at RT in PBS (137 mM NaCl, 3 mM KCl, 10 mM sodium phosphate, pH 7.0) at a concentration of 10 mg of brain per milliliter.

• 10 mg/ml frozen brain homogenate aliquots were thawed and diluted 10-fold in binding buffer to 1 mg/ml.

• 500 μl of appropriate concentrations of non-radioactive compound combined with 400 μl of [H-3]-AV-1451 in a volume of 900 ml of binding buffer. The final concentration of [H-3]-AV-1451 is typically 1-2 nM.

• After incubation at RT for 60 min, the binding mixture is filtered through a Whatman GF/B glass filter and washed 5 times with 3 ml binding buffer.

• Filters are counted in Cytoscint-ES after sitting in the cocktail overnight.

• Complete (100%) inhibition of binding is defined as the number of counts displaced by 3 μM non-radioactive T807.
Very strong binding in the HF and EC, frontal, temporal, parietal and occipital cortices in brain slices containing robust loads of NTF from AD brains. Binding was almost completely blocked by cold tracer. No binding in control brains free of NFT pathology.

PET images are courtesy of Dr. Keith Johnson.
Absence of detectable AV-1451 binding in slices containing non-PHF-tau lesions, except for incidental binding to age-related NFT in the EC (Braak stage II).

No labeling in brains of aged rTg4510 mice containing innumerable P301L (4R) tau lesions.
No detectable AV-1451 autoradiographic signal in slices from CAA (D23N Iowa APP mutation), DLB, MSA and FTLD-TDP-43 cases.
Dipping of adjacent brain slices in photographic nuclear emulsion showed strong and selective concentration of silver grains in gray matter of AD brains, reflecting underlying [F-18]-AV-1451 binding.

Laminar distribution of silver grains closely mirrored PHF-1 immunostaining.

Marquie et al. Ann Neurol 2015
**[F-18]-AV-1451 nuclear emulsion autoradiography: PHF-tau deposits**

Nuclear emulsion followed by IHC further confirmed that [F-18]-AV-1451-labeled lesions were PHF-tau containing deposits, including classic NFT (intra and extraneuronal) and PHF-tau containing neurites.

These lesions likely account for the majority of the observed in vivo signal in patients with AD.

Marquie et al. Ann Neurol 2015

PET images are courtesy of Dr. Keith Johnson
(2) [F-18]-AV-1451 nuclear emulsion autoradiography: \(\text{A}\beta\) deposits

No silver grains colocalizing with \(\text{A}\beta\) deposits in the form of plaques or CAA.
Negligible number of silver grains/no grains colocalizing with tau deposits in PiD, PSP and CBD cases, or with inclusions containing α-synuclein or TDP-43.
Intriguing but frequent findings emerging from early [F-18]-AV-1451 PET imaging studies

PET images are courtesy of Dr. Keith Johnson
(1) **[F-18]-AV-1451 phosphor screen autoradiography: off-target binding in the midbrain**

---

**Substantia Nigra**

- **CTL**
  - [F-18]-AV-1451 blocking

- **AD**
  - [F-18]-AV-1451 blocking

- **PSP**
  - [F-18]-AV-1451 blocking

- **DLB**
  - [F-18]-AV-1451 blocking

---

*PET images are courtesy of Dr. Keith Johnson*

---

**Marquie et al. Ann Neurol 2015**

*Strong binding of [F-18]-AV-1451 to midbrain slices containing substantia nigra regardless of the presence of underlying tau deposits.*

*Binding is almost completely blocked after incubation with unlabeled AV-1451.*
(2) **[F-18]-AV-1451 autoradiography:** off-target binding to neuromelanin- and melanin-containing cells

Marquie et al. Ann Neurol 2015
(2) [F-18]-AV-1451 autoradiography: weaker off-target binding to brain hemorrhagic lesions

Some [F-18]-AV-1451 binding in brain slices containing recent brain hemorrhagic lesions but no detectable binding to iron deposits.
In vivo tracer uptake in basal ganglia may represent nonspecific binding influenced by biological or technical factors other than underlying tau pathology.
(2) [H-3]-AV-1451 binding assay:

Pathologic diagnosis
Conclusions

- Our data derived from [F-18]-AV-1451-sensitive autoradiography and [H-3]-AV-1451 in vitro binding assays suggest that this tracer strongly binds to lesions primarily made of tau in the form of PHF (e.g., neurofibrillary tangles and PHF-tau containing neurites).

- [F-18]-AV-1451 does not bind to a significant extent to neuronal and glial inclusions mainly composed of straight tau filaments (non-AD tauopathies) or to Aβ deposits, α-synuclein and TDP-43 inclusions.

- [F-18]-AV-1451 shows strong off-target binding to neuromelanin- and melanin-containing cells, and some weaker off-target binding to brain hemorrhagic lesions.
Acknowledgements

Funding support:
- NIH Grant U01 AG016976
- NIH Grant R01 AG43511
- P50AG016574
- ASISA foundation, Spain

*M Avid/Lilly provided AV-1451 fluorescent analogues
* Dr. Peter Davies kindly provided PHF1 antibody
How do we reconcile our findings with some findings communicated by others from early [F-18]-AV-1451 PET imaging studies in PSP patients?